PDGFRB
Biomarker
PDGFRB alterations are involved in certain myeloid and solid tumors. Detection may guide use of targeted kinase inhibitors.
Approvals
1
Indications
1
Therapies
1
Mapped tests
1
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Indication-specific approvals
Approvals where PDGFRB is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Myelodysplastic Syndromes (MDS) Heme · Bone Marrow |
|
Tumor-agnostic approvals
Approvals defined at the solid tumor level where PDGFRB is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report PDGFRB as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Test
PDGFRB FISH Assay
ARUP Laboratories, Inc.
Method
FISH
Specimen
Bone marrow
Reports PDGFRB as part of its biomarker panel.
1 approvalView test profile →